Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	523.53	482.38	401.86	365.98	353.87	306.49
Revenue Growth (YoY)	26.51%	20.04%	9.80%	3.42%	15.46%	21.99%
Cost of Revenue	7.63	6.48	5.39	5.28	5.58	5.5
Gross Profit	515.9	475.89	396.47	360.7	348.29	300.98
Selling, General & Admin	191.96	184.26	152.85	122.36	105.33	100.36
Research & Development	202.01	184.35	130.99	113.86	114.76	89.02
Operating Expenses	393.97	368.61	283.84	236.22	220.09	189.38
Operating Income	121.93	107.28	112.63	124.48	128.2	111.61
Interest Expense / Income	-19.19	-17.28	-3.56	-0.53	-3.4	-5.07
Other Expense / Income	0.84	0.64	0.13	-	-	-
Pretax Income	140.28	123.91	116.06	125.01	131.6	116.68
Income Tax	23.09	18.42	14.77	12.49	25.59	22.5
Net Income	117.19	105.5	101.29	112.51	106.01	94.18
Net Income Growth	24.28%	4.15%	-9.98%	6.13%	12.56%	24.89%
Shares Outstanding (Basic)	103	104	107	116	115	114
Shares Outstanding (Diluted)	110	112	116	126	124	123
Shares Change	-4.77%	-3.64%	-7.94%	1.42%	1.33%	-3.25%
EPS (Basic)	1.15	1.02	0.95	0.97	0.92	0.82
EPS (Diluted)	1.06	0.94	0.87	0.89	0.85	0.77
EPS Growth	29.27%	8.05%	-2.25%	4.71%	10.39%	28.33%
Free Cash Flow	124.7	126.9	119.91	167.42	150.73	135.03
Free Cash Flow Per Share	1.21	1.23	1.12	1.45	1.31	1.18
Gross Margin	98.54%	98.66%	98.66%	98.56%	98.42%	98.20%
Operating Margin	23.29%	22.24%	28.03%	34.01%	36.23%	36.41%
Profit Margin	22.38%	21.87%	25.20%	30.74%	29.96%	30.73%
Free Cash Flow Margin	23.82%	26.31%	29.84%	45.75%	42.59%	44.06%
Effective Tax Rate	16.46%	14.86%	12.73%	9.99%	19.45%	19.28%
EBITDA	122.89	109	115.95	127.95	130.44	113.78
EBITDA Margin	23.47%	22.60%	28.85%	34.96%	36.86%	37.12%
Depreciation & Amortization	1.8	2.36	3.45	3.48	2.24	2.17
EBIT	121.09	106.64	112.5	124.48	128.2	111.61
EBIT Margin	23.13%	22.11%	28.00%	34.01%	36.23%	36.41%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).